Researchers find that giving tranexamic acid to women with placenta previa undergoing cesarean birth leads to a significant reduction in severe bleeding after delivery, with no increase in serious adverse events.
Tranexamic acid, a drug widely used to prevent or reduce heavy bleeding after surgery or trauma, has been found to significantly reduce severe bleeding in high-risk cesarean births. A recent trial published in the British Medical Journal found that giving tranexamic acid to women with placenta previa, a condition where the placenta covers the cervical opening, led to a 15% reduction in postpartum hemorrhage. This reduction in bleeding is modest but significant, particularly for women at high risk of harm from bleeding.
The trial included 1,694 pregnant women with placenta previa who were scheduled for cesarean delivery at 24 maternity units across China. Participants received prophylactic oxytocin, a standard treatment to reduce blood loss after delivery, and were randomly assigned to receive either intravenous tranexamic acid or a placebo. The results showed that prophylactic tranexamic acid reduced the rate of postpartum hemorrhage from 35.1% to 29.7% compared to the placebo group. This means that for every 19 women receiving prophylactic tranexamic acid, one case of postpartum hemorrhage would be prevented.
The researchers acknowledge that the findings are specific to women with placenta previa receiving prophylactic oxytocin and may not apply to other obstetric populations. However, the trial was well-designed, and the results were consistent after further analyses, suggesting that the findings are robust. The researchers conclude that prophylactic tranexamic acid leads to a statistically significant but modest reduction in the incidence of postpartum hemorrhage in high-risk women undergoing cesarean delivery.
In a linked editorial, UK researchers point out that this modest reduction in bleeding understates the impact, particularly in women at high risk of harm from bleeding. They recommend evaluating pre-incision administration of tranexamic acid for cesarean section, while carefully monitoring maternal and neonatal outcomes. The focus should now shift from whether tranexamic acid reduces bleeding to how it is used to maximize patient benefit.
The use of tranexamic acid in preventing postpartum hemorrhage has been studied in various trials, with mixed results. However, this recent trial provides new evidence on the effectiveness of tranexamic acid in reducing bleeding in high-risk cesarean births. The findings of this trial are significant, as they provide a new option for reducing bleeding in women with placenta previa undergoing cesarean delivery. Further studies are needed to validate these results and to identify specific patient subgroups most likely to benefit from prophylactic use of tranexamic acid.
In conclusion, the use of tranexamic acid in high-risk cesarean births has the potential to significantly reduce severe bleeding after delivery. While the reduction in bleeding is modest, it is significant, particularly for women at high risk of harm from bleeding. Further studies are needed to evaluate the effectiveness of tranexamic acid in different obstetric populations and to identify the best way to use this drug to maximize patient benefit. As research continues to uncover the benefits and risks of tranexamic acid, it is likely that this drug will become an important tool in reducing bleeding in high-risk cesarean births.
